Colorectal Cancer: Innovations in Screening, Diagnosis and Treatment

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1793

Special Issue Editors

E-Mail Website
Guest Editor
1. Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
2. Radiology of Faenza, Medical Imaging Department AUSL Romagna, 48018 Faenza, Italy
Interests: video-assisted thoracic surgery; hepatocellular carcinoma; teleradiology; cancer; gastrointestinal diseases; diagnosis; colonoscopy; applied artificial intelligence; endometriosis; liver diseases

E-Mail Website
Guest Editor
Academic Radiology, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, 56126 Pisa, Italy
Interests: cancer imaging; imaging informatics (with a predominant focus on artificial intelligence, radiomics and structured reporting applied to cancer imaging); optimization of CT acquisition protocols
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the last few years, in medical imaging, new perspectives have been developed, especially related to the introduction of artificial intelligence (AI) and radiomics, making radiology a pivotal specialty of modern medicine.

Radiologists will attain better precision and effectiveness with the advent of AI technology, making machine-assisted medical services a valuable and important option for future oncologic medical care.

The purpose of this special issue is to overview the current evidence and future prospects of AI and radiomics algorithms in the screening, diagnosis and treatment of colorectal cancer.

Dr. Francesca Coppola
Dr. Lorenzo Faggioni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.



  • colorectal cancer
  • radiomics
  • deep learning
  • artificial intelligence
  • cancer imaging
  • machine learning
  • oncology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


15 pages, 1820 KiB  
The Composition of Small Extracellular Vesicles (sEVs) in the Blood Plasma of Colorectal Cancer Patients Reflects the Presence of Metabolic Syndrome and Correlates with Angiogenesis and the Effectiveness of Thermoradiation Therapy
by Natalia V. Yunusova, Dmitry A. Svarovsky, Artem I. Konovalov, Dmitry N. Kostromitsky, Zhanna A. Startseva, Olga V. Cheremisina, Sergey G. Afanas’ev, Irina V. Kondakova, Alina E. Grigor’eva, Sergey V. Vtorushin, Elena E. Sereda, Anna V. Usova and Svetlana N. Tamkovich
J. Pers. Med. 2023, 13(4), 684; - 19 Apr 2023
Cited by 1 | Viewed by 1499
The majority of colorectal cancer patients (CRCPs) develop tumors on the background of “metabolically healthy obesity” or metabolic syndrome. The aim of the work was to study the levels of matrix metalloproteinases (MMPs) and heat shock proteins (HSPs) on the surface of blood [...] Read more.
The majority of colorectal cancer patients (CRCPs) develop tumors on the background of “metabolically healthy obesity” or metabolic syndrome. The aim of the work was to study the levels of matrix metalloproteinases (MMPs) and heat shock proteins (HSPs) on the surface of blood plasma CD9-positive and FABP4-positive small extracellular vesicles (sEVs) from CRCPs depending on metabolic status and tumor angiogenesis, as well as to evaluate the sEVs markers as predictors of the effectiveness of thermoradiotherapy. In CRCPs, compared with patients with colorectal polyps (CPPs), the proportion of triple positive EVs and EVs with the MMP9+MMP2-TIMP1+ phenotype increased significantly among FABP4-positive EVs (adipocyte-derived EVs), which in general may indicate the overexpression of MMP9 and TIMP1 by adipocytes or adipose tissue macrophages in CRCPs. The results obtained have prospects for use as markers to clarify cancer risk in CPPs. One can assume that for CRCPs with metabolic syndrome or metabolically healthy obesity, it is the FABP4+MMP9+MMP2-TIMP1- population of circulating sEVs that is the most optimal biomarker reflecting tumor angiogenesis. Determining this population in the blood will be useful in monitoring patients after treatment for the early detection of tumor progression. CD9+MMP9+MMP2-TIMP1- and MMP9+MMP2-TIMP1+ subpopulations of circulating sEVs are the most promising predictors of the efficacy of thermoradiation therapy because their levels at baseline differ significantly in CRCPs with different tumor responses. Full article
(This article belongs to the Special Issue Colorectal Cancer: Innovations in Screening, Diagnosis and Treatment)
Show Figures

Figure 1

Back to TopTop